A recent systematic review and meta-analysis of 10 double-blind randomised controlled studies including 6456 people has found that adding a DPP-4 inhibitor (or gliptin) to a sulfonylurea increases the risk of hypoglycaemia by about 50%.
People at high risk of developing Type 2 diabetes can reduce their chances of getting the condition by more than 80% by completing a new education programme, according to a new study from the Leicester Diabetes Centre.
A large international study (INTERSTROKE) in 27,000 patients highlights the importance of managing hypertension and other modifiable risk factors in stroke prevention. A total of 90% of the risk of stroke is accounted for by 10 modifiable risk factors.
A new Cochrane Review highlights the value of nurse-led titration of ACE inhibitors, beta-blockers and angiotensin II receptor blockers in patients with chronic heart failure. All-cause mortality and hospitalisations were lower in the nurse-led titration group compared with the usual care of titration by GPs.
Drugs used to treat diabetes could also be used to treat Alzheimer’s disease, and vice versa, according to new basic research from the University of Aberdeen. This is also the first study of its kind to show that Alzheimer’s disease can lead to diabetes, as opposed to diabetes occurring first as was previously thought.
Bariatric surgery on some obese patients with type 2 diabetes could result in lifetime savings of about £95,000 per patient, mostly due to reduced medication costs, according to data presented at the recent European Obesity Congress in Gothenburg, Sweden.
A 20-year study demonstrates that higher levels of cardiorespiratory fitness reduce the risk for developing prediabetes or diabetes. This is the longest study conducted in this area and provides strong evidence that supports the commonly accepted view that fitness is beneficial in reducing the risk for prediabetes and diabetes.
New data from the EMPA-REG OUTCOME and LEADER trials presented at the recent American Diabetes Association meeting show that the SGLT-2 inhibitor empagliflozin and the GLP-1 receptor analogue liraglutide significantly reduce cardiovascular mortality and cardiovascular events in high-risk type 2 diabetes patients.